BMR vs INLX

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and no available Altman Z-Score prevents a full distress risk assessment. Despite a strong gross margin of 90.23% and a low Debt/Equity ratio of 0.01, the company is deeply unprofitable with negative operating and net margins of -320.04% and -146.06%, respectively. Revenue growth is minimal at 6.70% YoY, while market performance has been severely negative, with a 1-year return of -52.7%. Valuation metrics like Price/Sales of 9.47 appear high relative to peers and fundamentals, suggesting limited upside without a turnaround.

The company exhibits severe financial weakness, highlighted by a Piotroski F-Score of 2/9, placing it firmly in the 'Weak' health category. Despite a strong gross margin of 66.05%, the business is struggling with stagnant revenue growth (1.00% YoY) and negative profitability (ROE -17.01%). The technical trend is completely bearish (0/100), and the stock has lost over 53% of its value in the last year. With a Forward P/E of 116.67 and no meaningful growth catalysts, the current valuation is difficult to justify.